 | |
 | |
| Clinical data | |
|---|---|
| Other names | MALT; N,N-Methylallyltyptamine |
| Routes of administration | Oral, smoking, vaping[1] |
| Drug class | Serotonin receptor modulator; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Onset of action | Unknown[1][2] |
| Duration of action | Unknown[1][2] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H18N2 |
| Molar mass | 214.312ย gยทmolโ1 |
| 3D model (JSmol) | |
| |
| |
Methylallyltryptamine (MALT), also known as N-methyl-N-allyltryptamine, is a lesser-known psychedelic drug from the tryptamine family.[1] It is a novel compound with very little history of human use.[1] It is closely related to methylpropyltryptamine (MPT).[1] The drug has been sold online as a designer drug.[1] Very little information on the pharmacology or toxicity of MALT is available.[citation needed]
Use and effects
editMALT was not included in Alexander Shulgin's 1997 book TiHKAL (Tryptamines I Have Known and Loved).[2] However, years after the book's publication, he described MALT as having important unexplored potential as a psychedelic drug.[3] Subsequently, MALT was encountered as a novel designer drug.[1] It has been reported to have been used at doses of 25 to 50ย mg via routes including oral, smoking, or vaping.[1] The drug's effects have been described as comparable to those of methylpropyltryptamine (MPT) but less pronounced.[1]
Interactions
editPharmacology
editPharmacodynamics
editMALT is a serotonin receptor modulator and has been found to interact with the serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors.[4]
Chemistry
editAnalogues
editAnalogues of MALT include 4-HO-MALT, 4-AcO-MALT, 5-MeO-MALT, diallyltryptamine (DALT), methylpropyltryptamine (MPT), and methylisopropyltryptamine (MiPT), among others.
History
editMALT was first described in the scientific literature by Niels Jensen of the University of Gรถttingen by 2004.[4] The drug was subsequently first encountered as a novel designer drug by 2018.[1]
Society and culture
editLegal status
edit
MALT is not explicitly scheduled in any countries; however, it could be considered a psychoactive substance under the United Kingdom Psychoactive Substances Act, which requires the prosecutor to prove that the substance is psychoactive in order for a person to be charged with an offense.[5] It could also be considered a structural analogue of a scheduled substance under the United States Federal Analogue Act due to its similarity to scheduled tryptamines. It is not a controlled substance in Canada as of 2025.[6]
See also
editReferences
edit- ^ a b c d e f g h i j k "MALT". ะะะะกะะ (in Russian). Retrieved 2 January 2026.
- ^ a b c Shulgin A, Shulgin A (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBNย 0-9630096-9-9. OCLCย 38503252.
- ^ Morris H (2014). "Alexander Shulgin (1925โ2014)". The Fabulist. No.ย 5.
On that day in 2010, Alexander Shulgin was sitting outside under a parasol in his front yard surrounded by admirers, looking very happy, and talking discursively about the unexplored potential in 5-ethoxylated tryptamines and asymmetrical N-allyl-tryptamines such as MAlT, EAlT, PAlT, and iPAlT
- ^ a b Jensen N (2004). Tryptamines as Ligands and Modulators of the Serotonin 5โHT2A Receptor and the Isolation of Aeruginascin from the Hallucinogenic Mushroom Inocybe aeruginascens (PDF) (Thesis). Georg-August-University Gรถttingen. doi:10.53846/goediss-2111.
- ^ "Psychoactive Substances Act Guidance" (PDF). The Crown Prosecution Service. Retrieved 2021-09-23.
- ^ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
